Aluminum Hydroxide
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Drug reference
Paricalcitol
Vitamin · Management of secondary hyperparathyroidism
VitaminManagement of secondary hyperparathyroidism
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
10 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 10 →
- Aluminum HydroxideSevereDatabaseDDInter
- BurosumabSevereDatabaseDDInter
- CalcifediolSevereDatabaseDDInter
- CalcitriolSevereDatabaseDDInter
Mechanism
Paricalcitol is a synthetic vitamin D analogue. It is used for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease.
Indications
Prevention and treatment of secondary hyperparathyroidism associated with chronic kidney diseasePrevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in patients on haemodialysissecondary hyperparathyroidism in patients with chronic kidney disease (CKD)
Dosing
- Adult
- Oral: Consult product literature. Parenteral (via haemodialysis access): Consult product literature.
Side effects
Common
Electrolyte imbalanceHypoparathyroidismTaste altered
Serious
- Angioedema
- Laryngeal oedema
- Cardiac arrest
- Cerebrovascular insufficiency
- Coma
- Pneumonia
- Arrhythmias
- Asthma
- Breast cancer
Drug interactions
Burosumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Calcifediol
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Calcitriol
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Cholecalciferol
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Dihydrotachysterol
Severe
Database
Clinical effect not specified
Source: DDInter
Doxercalciferol
Severe
Database
Clinical effect not specified
Source: DDInter
Erdafitinib
Severe
Database
Drug interaction classified as: others
Source: DDInter
Ergocalciferol
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Sucralfate
Severe
Database
Clinical effect not specified
Source: DDInter
2 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Acute kidney injury
KDIGO · Nephrology · 2012
Chronic kidney disease — assessment and management
NICE · Nephrology · 2021
Stroke and TIA — secondary prevention
AHA · Neurology · 2021
Cardiovascular disease prevention
ESC · Cardiology · 2021
Other Vitamin drugs
Ask House about Paricalcitol
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team